193 related articles for article (PubMed ID: 19076156)
21. Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Ekhart C; Kerst JM; Rodenhuis S; Beijnen JH; Huitema AD
Cancer Chemother Pharmacol; 2009 Jan; 63(2):375-9. PubMed ID: 18431571
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects.
Hagen B
Cancer Chemother Pharmacol; 1991; 27(5):373-8. PubMed ID: 1705489
[TBL] [Abstract][Full Text] [Related]
23. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
Gor PP; Su HI; Gray RJ; Gimotty PA; Horn M; Aplenc R; Vaughan WP; Tallman MS; Rebbeck TR; DeMichele A
Breast Cancer Res; 2010; 12(3):R26. PubMed ID: 20459744
[TBL] [Abstract][Full Text] [Related]
24. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.
Kirchheiner J; Klein C; Meineke I; Sasse J; Zanger UM; Mürdter TE; Roots I; Brockmöller J
Pharmacogenetics; 2003 Oct; 13(10):619-26. PubMed ID: 14515060
[TBL] [Abstract][Full Text] [Related]
25. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
de Jonge ME; Mathôt RA; Dalesio O; Huitema AD; Rodenhuis S; Beijnen JH
Bone Marrow Transplant; 2002 Nov; 30(9):593-7. PubMed ID: 12407434
[TBL] [Abstract][Full Text] [Related]
26. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
[TBL] [Abstract][Full Text] [Related]
27. Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.
Chou M; Bertrand J; Segeral O; Verstuyft C; Borand L; Comets E; Le Tiec C; Becquemont L; Ouk V; Mentre F; Taburet AM
Antimicrob Agents Chemother; 2010 Oct; 54(10):4432-9. PubMed ID: 20696882
[TBL] [Abstract][Full Text] [Related]
28. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.
Huang L; Winger BA; Cheah V; Gingrich D; Marzan F; Lu Y; Cooper JC; Aweeka F; Long-Boyle J
J Chromatogr Open; 2022 Nov; 2():. PubMed ID: 35875822
[TBL] [Abstract][Full Text] [Related]
29. A search for new metabolites of N,N',N''-triethylenethiophosphoramide.
van Maanen MJ; Tijhof IM; Damen JM; Versluis C; van den Bosch JJ; Heck AJ; Rodenhuis S; Beijnen JH
Cancer Res; 1999 Sep; 59(18):4720-4. PubMed ID: 10493531
[TBL] [Abstract][Full Text] [Related]
30. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
31. Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.
van Maanen RJ; van Ooijen RD; Zwikker JW; Huitema AD; Rodenhuis S; Beijnen JH
J Chromatogr B Biomed Sci Appl; 1998 Nov; 719(1-2):103-12. PubMed ID: 9869370
[TBL] [Abstract][Full Text] [Related]
32. CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
Ramírez J; Innocenti F; Schuetz EG; Flockhart DA; Relling MV; Santucci R; Ratain MJ
Drug Metab Dispos; 2004 Sep; 32(9):930-6. PubMed ID: 15319333
[TBL] [Abstract][Full Text] [Related]
33. Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism.
Rae JM; Soukhova NV; Flockhart DA; Desta Z
Drug Metab Dispos; 2002 May; 30(5):525-30. PubMed ID: 11950782
[TBL] [Abstract][Full Text] [Related]
34. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
[TBL] [Abstract][Full Text] [Related]
35. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites.
Cohen BE; Egorin MJ; Kohlhepp EA; Aisner J; Gutierrez PL
Cancer Treat Rep; 1986 Jul; 70(7):859-64. PubMed ID: 2424593
[TBL] [Abstract][Full Text] [Related]
36. Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen.
Huitema AD; Mathôt RA; Tibben MM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2001 Dec; 23(6):650-7. PubMed ID: 11802099
[TBL] [Abstract][Full Text] [Related]
37. Influence of co-medicated drugs on the biotransformation of thioTEPA to TEPA and thioTEPA-mercapturate.
van Maanen MJ; Huitema AD; Beijen JH
Anticancer Res; 2000; 20(3A):1711-6. PubMed ID: 10928097
[TBL] [Abstract][Full Text] [Related]
38. Cytochrome P450 (CYP3A4*18) and glutathione-S-transferase (GSTP1) polymorphisms in a healthy Tunisian population.
Zaied C; Abid S; Mtiraoui N; Zellema D; Achour A; Bacha H
Genet Test Mol Biomarkers; 2012 Oct; 16(10):1184-7. PubMed ID: 22971138
[TBL] [Abstract][Full Text] [Related]
39. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Jun; 27(3):393-402. PubMed ID: 15905813
[TBL] [Abstract][Full Text] [Related]
40. Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J; Sludden J; Griffin MJ; Cole M; Verrill M; Jamieson D; Boddy AV
Br J Cancer; 2010 Mar; 102(6):1003-9. PubMed ID: 20179710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
